1. Home
  2. ALLO vs CARE Comparison

ALLO vs CARE Comparison

Compare ALLO & CARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • CARE
  • Stock Information
  • Founded
  • ALLO 2017
  • CARE 1974
  • Country
  • ALLO United States
  • CARE United States
  • Employees
  • ALLO N/A
  • CARE N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • CARE Major Banks
  • Sector
  • ALLO Health Care
  • CARE Finance
  • Exchange
  • ALLO Nasdaq
  • CARE Nasdaq
  • Market Cap
  • ALLO 431.9M
  • CARE 453.4M
  • IPO Year
  • ALLO 2018
  • CARE N/A
  • Fundamental
  • Price
  • ALLO $2.07
  • CARE $18.48
  • Analyst Decision
  • ALLO Buy
  • CARE Buy
  • Analyst Count
  • ALLO 12
  • CARE 2
  • Target Price
  • ALLO $10.06
  • CARE $21.50
  • AVG Volume (30 Days)
  • ALLO 2.5M
  • CARE 81.8K
  • Earning Date
  • ALLO 11-07-2024
  • CARE 01-23-2025
  • Dividend Yield
  • ALLO N/A
  • CARE N/A
  • EPS Growth
  • ALLO N/A
  • CARE N/A
  • EPS
  • ALLO N/A
  • CARE 0.62
  • Revenue
  • ALLO $43,000.00
  • CARE $128,505,000.00
  • Revenue This Year
  • ALLO N/A
  • CARE N/A
  • Revenue Next Year
  • ALLO N/A
  • CARE $20.03
  • P/E Ratio
  • ALLO N/A
  • CARE $29.65
  • Revenue Growth
  • ALLO 26.47
  • CARE N/A
  • 52 Week Low
  • ALLO $1.83
  • CARE $10.95
  • 52 Week High
  • ALLO $5.78
  • CARE $20.40
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 41.06
  • CARE 45.23
  • Support Level
  • ALLO $1.83
  • CARE $18.27
  • Resistance Level
  • ALLO $2.09
  • CARE $19.47
  • Average True Range (ATR)
  • ALLO 0.14
  • CARE 0.43
  • MACD
  • ALLO -0.01
  • CARE -0.07
  • Stochastic Oscillator
  • ALLO 30.38
  • CARE 17.50

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About CARE Carter Bankshares Inc.

Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. The Bank offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.

Share on Social Networks: